The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome

Annals of Clinical Biochemistry

Volumn 40, Issue 3, 2003, Pages 219-231

  Spencer, Kevin ^a   Crossley, J A ^b   Aitken, D A ^b   Nix, A B J ^c   Dunstan, F D J ^c   Williams, K ^c  

^a HAROLD WOOD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ACCURACY; ADULT; ALGORITHM; ARTICLE; CASE REPORT; COMPARATIVE STUDY; COMPUTER SIMULATION; CORRELATION COEFFICIENT; DIAGNOSTIC ERROR; DISEASE MARKER; DOWN SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; HUMAN; LABORATORY DIAGNOSIS; PREGNANCY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; STATISTICAL MODEL; TRISOMY 21;

ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; FLUORENES; GESTATIONAL AGE; HUMANS; HYDANTOINS; ODDS RATIO; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; RISK ASSESSMENT;

EID: 0038366552     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/000456303321610501     Document Type: Article

References (20)

1. Aitken DA, Crossley JA, Spencer K. Prenatal screening for neural tube defects and aneuploidy. In: Rimoin DL, Connor JM, Pyeritz RE, Korf BR, eds. Emery and Rimoin's Principles and Practice of Medical Genetics, 4th edn. London: Churchill Livingstone, 2002: 763-801
2. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988; 297: 883-7
3. Reynolds TM, Penney MD. The mathematical basis of multivariate risk screening: with special reference to screening for Down's syndrome associated pregnancy. Ann Clin Biochem 1990; 27: 452-8
4. Weyland B, Greenberg F, Del Junco D, Fawcett WA, Schmidt D, Rose E, et al. Does gestational age affect the detection rate of maternal serum alpha-fetoprotein screening for Down's syndrome? Am J Hum Genet 1989; 45: A273
5. Macri JN, Kasturi RV, Krantz DA, Cook EJ, Moore ND, Young JA, et al. Maternal serum Down syndrome screening: free beta protein is a more effective marker than human chorionic gonadotrophin. Am J Obstet Gynecol 1990; 163: 1248-53
6. Spencer K, Coombes EJ, Mallard AS, Ward AM. Free beta human chorionic gonadotropin in Down's syndrome screening: a multicentre study of its role compared with other biochemical markers. Ann Clin Biochem 1993; 29: 506-18
7. Berry E, Aitken DA, Crossley JA, Macri JN, Connor JM. Screening for Down's syndrome: changes in marker levels and detection rates between the first and second trimesters. Br J Obstet Gynaecol 1997; 104: 811-7
8. Spencer K, Crossley JA, Aitken DA, Nix ABJ, Dunstan FDJ, Williams K. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 2002; 39: 567-76
9. Bishop JC, Dunstan FDJ, Nix ABJ, Reynolds T. Detection rates and false positive rate for Down syndrome screening: how accurately can they be estimated and what factors influence their value? Stat Med 1997; 16: 1481-95
10. Office for National Statistics. Birth Statistics. Series FM1 No. 27. London: The Stationery Office, 1998
11. Williams KL, Nix AJB, Dunstan FDJ. Effect of screening algorithm, parameter values and median smoothing on patient-specific risk estimates for Down's syndrome screening. Ann Clin Biochem 2000; 37: 165-73
12. Wald NJ, George L, Smith D, Densem JW, Petterson K. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. Br J Obstet Gynaecol 1996; 103: 407-12
13. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 1999; 13: 231-7
14. Cuckle H. Improved parameters for risk estimation in Down's syndrome screening. Prenat Diagn 1995; 15: 1057-65
15. Cuckle HS, van Lith JMM. Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat Diagn 1999; 19: 505-12
16. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynaecol 2000; 107: 1271-5
17. Crossley JA, Aitken DA, Cameron AD, McBride E, Connor JM. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicentre study. Br J Obstet Gynaecol 2002; 109: 667-76
18. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. One stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15030 pregnancies. Ultrasound Obstet Gynecol 2002; 20: 219-25
19. Aitken DA, Wallace EM, Crossley JA, Swanston IA, van Pareren Y, van Maarle M, et al. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. N Engl J Med 1996; 334: 1231-6
20. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. J Med Screen 1997; 4: 181-246